Articles & practical guides
Practical, evidence-anchored articles on the questions people actually ask about GLP-1 medications, peptides, and obesity therapy. Head-to-head comparisons, side-effect timelines, prevention strategies, and the long-term considerations that don't fit neatly into a peptide page.
How this section works
The articles below are written to answer specific questions, the ones people actually search for when they're navigating GLP-1 therapy or peptide research. Each article includes a 60-second TL;DR at the top, structured sections with the substantive answer, key takeaways, and an FAQ. We cite the underlying research throughout and link to the peptide pages where the deeper evidence lives.
If you want the comprehensive evidence base on a specific compound, the peptide pages are the right place. If you want a practical read on a specific contested claim, the Evidence vs Myth section is the right place. This Articles section is for the practical, "how do I actually navigate this?" questions.
Head-to-head comparisons · 23 articles
Direct comparisons between commonly-paired peptides and drugs, what the evidence shows about which is right for whom.
Semaglutide vs Tirzepatide for Weight Loss: A 2026 Comparison
The most-asked comparison in modern obesity medicine. We work through the head-to-head trial data, the dual-agonist mechanism that makes tirzepatide deeper, the cardiovascular evidence semaglutide has and tirzepatide doesn't yet, and which one fits which patient.
Read articleMounjaro vs Zepbound: Yes, They're the Same Drug (Tirzepatide) — 2026 Guide
Two brand names, two indications, identical molecules. Mounjaro and Zepbound are both tirzepatide from Eli Lilly — the difference is regulatory packaging, not pharmacology. This explains why one drug has two names, what's actually different for cost and coverage in 2026, how switching works, and what changes after the compounded-tirzepatide shortage resolution.
Read articleSemaglutide vs Ozempic vs Wegovy vs Rybelsus: Why Four Names for One Drug?
All four names refer to semaglutide, the same molecule, manufactured by Novo Nordisk. The differences are in dose, indication, formulation, and brand. Each name maps to a specific combination of those, and knowing which is which makes the conversation with your doctor easier.
Read articleBPC-157 vs TB-500: Which to Choose for Recovery?
The two most-discussed recovery peptides in modern community use, often paired together. This compares them mechanistically, weighs the evidence each has independently, and asks whether the combination beats either alone.
Read articleSermorelin vs CJC-1295 vs Modified GRF 1-29: A GHRH Analog Comparison
Three of the most commonly-discussed GHRH analog peptides for endogenous GH and IGF-1 elevation. They differ more than the shared mechanism suggests: which fits which use case, and what the evidence supports.
Read articleOzempic vs Wegovy: The Same Drug Under Different Names
Two brand names, two FDA-approved indications, one molecule. The split is regulatory and commercial rather than pharmacological: what makes the brands clinically distinct, and how to navigate which one you're prescribed.
Read articleLiraglutide vs Semaglutide: When the Older GLP-1 Still Fits
Semaglutide has largely supplanted liraglutide in the GLP-1 market, but liraglutide isn't obsolete. The older daily-injection GLP-1 still holds specific advantages, and the newer weekly options are clearly superior elsewhere.
Read articleGHRP-2 vs GHRP-6 vs Ipamorelin: Selectivity Trade-offs in the Ghrelin Mimetic Class
Three of the most-discussed ghrelin receptor agonists for GH release. Same general mechanism, very different selectivity profiles. This compares them on cortisol, prolactin, and appetite effects, and on which fits which use case.
Read articleSaxenda vs Victoza: The Two Faces of Liraglutide
Saxenda and Victoza are the same molecule, liraglutide, sold at different doses for different indications. Here is what the brand-name split actually means for dosing, coverage, side effects, and why one is an obesity drug and the other a diabetes drug despite identical chemistry.
Read articleByetta vs Bydureon: The Two Faces of Exenatide
Byetta and Bydureon are the same molecule, exenatide, sold at different dosing frequencies for different patient profiles. Here is what the brand-name split actually means, why one was the first FDA-approved GLP-1 ever, and why the other introduced the once-weekly format the entire class now follows.
Read articleTrulicity vs Ozempic: Which Once-Weekly GLP-1 for Type 2 Diabetes?
Trulicity (dulaglutide) and Ozempic (semaglutide) are the two most-prescribed once-weekly GLP-1 drugs for type 2 diabetes. Here is how they actually compare on efficacy, cardiovascular outcomes data, dosing, side effects, and which patient profile fits which drug.
Read articlePemvidutide vs Survodutide vs Retatrutide: The Glucagon-Arm Comparison
Three Phase 3 obesity drugs incorporate the glucagon receptor, the novel arm that increases energy expenditure and liver fat breakdown. Pemvidutide and survodutide are GLP-1/glucagon duals; retatrutide adds GIP for a triple. Here is how they compare on efficacy, MASH potential, and where each fits.
Read articleTesamorelin vs GHRPs vs HGH: Three Routes to GH Optimization
Three distinct approaches to elevating GH activity: direct HGH, the GHRH-analog tesamorelin, and ghrelin-receptor agonists like ipamorelin. Here is how they actually compare on mechanism, magnitude, evidence quality, regulatory exposure, and cost, and which approach fits which goal.
Read articleMOTS-c + SS-31: Better Together or Separate?
Two of the most-discussed mitochondrial peptides target the same organelle through very different mechanisms, one as a signaling molecule, the other as a structural protector. Whether to combine them or use them separately is one of the most-asked questions in the longevity-peptide community. A practical walk through the mechanistic case, what each does alone, and how to decide.
Read articleTesofensine vs Semaglutide for Weight Loss: A Mechanism-First Comparison
Two fundamentally different approaches to pharmacological weight loss, central monoamine reuptake inhibition vs peripheral incretin signaling. A walk through what each does, what the trial data shows, who fits which, and when sequential or combined use makes sense.
Read articleCagriSema Explained: How the Amylin + GLP-1 Combination Works
Novo Nordisk's cagrilintide + semaglutide combination has produced the most-anticipated Phase 3 readout in obesity pharmacology since SURMOUNT-1. The REIMAGINE 1 results, the mechanism behind why two pathways outperform one, and how the amylin axis changes what's possible, calibrated against semaglutide alone and the broader incretin landscape.
Read article ArticleCopper Peptides vs CoQ10 for Skin Aging: Which Has Better Evidence?
GHK-Cu signals the skin to rebuild its matrix; coenzyme Q10 is an antioxidant that declines with age. They are not substitutes. What the evidence supports for each, and which is gentler if irritation is the deciding factor.
Read articleGHK-Cu vs AHK-Cu: Should You Add AHK-Cu to Your Stack?
Both are copper-binding tripeptides. Both show up in YouTube biohacker content. But they're not interchangeable, they engage different aspects of skin and hair biology, and the case for stacking them depends entirely on what you're actually trying to accomplish. A decision-framework walk-through for users already on GHK-Cu wondering whether AHK-Cu is worth adding.
Read articleWegovy vs Zepbound: The Two FDA-Approved Obesity Meds Compared (2026)
Two branded weight-loss medications, two different molecules, two different manufacturers. Wegovy is semaglutide from Novo Nordisk; Zepbound is tirzepatide from Eli Lilly. Both are FDA-approved specifically for chronic weight management, both are administered once weekly, and both produce clinically meaningful weight loss. But the trial numbers, side-effect patterns, insurance coverage rules, and access options differ substantially. Those four differences are where the honest 2026 comparison actually lives.
Read articleRybelsus vs Ozempic: Oral vs Injectable Semaglutide, Which Is Right for You?
Same molecule, two different formats. Rybelsus is oral semaglutide taken as a daily tablet; Ozempic is injectable semaglutide taken as a weekly subcutaneous injection. Both are approved for type 2 diabetes; both are made by Novo Nordisk. Efficacy differs, dosing differs, and the patient experience differs enormously. This compares them on efficacy, dosing, and day-to-day experience in 2026.
Read articleOzempic vs Mounjaro for Type 2 Diabetes: The 2026 Head-to-Head
Two once-weekly diabetes medications from competing manufacturers. Ozempic is semaglutide from Novo Nordisk; Mounjaro is tirzepatide from Eli Lilly. Both are FDA-approved for type 2 diabetes. Both lower HbA1c and reduce weight. Direct head-to-head trial data (SURPASS-2) settled the efficacy comparison. This is what the numbers say, and what actually matters for diabetes management in 2026.
Read articleSemaglutide vs tirzepatide vs retatrutide
Head-to-head walkthrough of mechanism, weight-loss magnitude, side effects, and access for the three leading injectable agents, including retatrutide for the 3-way picture.
Read articleSingle, dual, and triple incretin agonists
How the class evolved from GLP-1-only to GLP-1/GIP and GLP-1/GIP/glucagon, and why receptor count is no longer the only story.
Read articleOral vs injectable GLP-1s
Rybelsus's strict timing, the emerging non-peptide class led by orforglipron, and the danuglipron lesson on safety stewardship.
Read articlePractical guides · 55 articles
Practical, evidence-based guides for the questions people actually ask about peptide and obesity-medicine therapy.
How to Evaluate a Peptide Vendor: A Due-Diligence Framework
The research-peptide market has no FDA gatekeeper, so the burden of judging quality falls on the reader. What the paperwork proves, what it doesn't, and where any due diligence runs out.
Read article ArticleFDA Moves to Keep Semaglutide and Tirzepatide Off the 503B Bulks List
FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no sufficient clinical need for outsourcing facilities to compound them from bulk. It would close the last broad route to large-scale compounded GLP-1 supply.
Read articleWhat GLP-1 Therapy Actually Costs in 2026
Branded GLP-1 drugs list for well over a thousand dollars a month, yet real out-of-pocket costs run from under $100 to full price. A map of why the numbers vary so much, and the cost that actually matters.
Read articleGLP-1s and Menopause: What Changes for Women at Midlife
Menopausal weight gain is biologically distinct, driven by falling estrogen, shifting fat storage, and accelerating muscle loss. How GLP-1 therapy fits, what to prioritize, and where the evidence is thin.
Read articleHow to Avoid Muscle Loss on GLP-1 Medications
About 25-40% of GLP-1-driven weight loss is lean mass, and that fact has driven both legitimate concern and substantial overstatement. The data separates the real risk from the overstatement: who is most affected, and which evidence-based interventions meaningfully reduce muscle loss without slowing fat loss.
Read articleBPC-157 Dosing for Tendon Injuries: What the Research Actually Suggests
The most-asked practical question about BPC-157. We walk through what the preclinical literature suggests about dosing, what the athletic and biohacker communities are actually doing, the regulatory considerations that shape availability, and the honest gap between rodent-protocol data and validated human protocols.
Read articleAre Research Peptides Legal in the United States in 2026?
The legal status of research peptides is more nuanced than either 'totally legal' or 'totally illegal' framings suggest. This lays out the actual federal framework, what the 'research use only' label does and doesn't mean, and where the gray areas live.
Read articleBest Peptide Stacks for Fat Loss: A 2026 Evidence-Based Review
Five peptide stacks ranked by how much actual human evidence supports the combination, what each accomplishes mechanistically, and where they fit in 2026's evolving obesity-pharmacology landscape. Plus the honest verdict on which combinations are validated, which are theoretical, and which are mostly community marketing.
Read articleSwitching from Semaglutide to Tirzepatide: A Practical Guide
A common transition with no formal dose-conversion protocol. What follows is what the clinical literature suggests about timing, what dose to start tirzepatide at, what to expect during the transition, and the situations where switching makes sense versus where it doesn't.
Read articleGLP-1 Microdosing: Real Strategy or Wishful Thinking?
The trend of using sub-therapeutic doses of semaglutide or tirzepatide for modest weight loss, metabolic improvement, or appetite control has grown substantially. The evidence on lower-dose effects is thinner than the trend suggests: who it might fit, and where the framing overstates what the data supports.
Read articleGLP-1 Plateau: How to Break Through Weight-Loss Stalls
Weight loss on GLP-1 therapy slows substantially after months 4-6 and often plateaus before goal weight is reached. This explains what is actually happening biologically, when a plateau is normal versus when intervention helps, and the strategies that produce additional weight loss when the medication alone has stopped working.
Read articleHow GLP-1s Work in Plain English: The Mechanism Explained
GLP-1 medications have become some of the most-prescribed drugs in modern medicine, but the actual mechanism isn't well-explained outside medical literature. This lays out the biology in clear language that doesn't require a pharmacology background.
Read articleCompounded Semaglutide vs Brand-Name Wegovy: Risk and Cost Trade-offs
Compounded semaglutide became widely available during the 2023-2024 shortage and has been substantially restricted since. What follows is where the regulatory landscape stands now, what compounded versions actually are, and an honest cost-vs-risk analysis.
Read articleHow Long Does BPC-157 Take to Work?
One of the most-asked practical questions about BPC-157, and one where the honest answer differs from marketing claims. What follows is what the rodent timelines suggest, what user reports describe, and realistic expectation-setting for different injury types.
Read articleBest Longevity Peptides in 2026: An Evidence-Based Ranking
The longevity peptide space ranges from FDA-approved compounds with cardiovascular outcomes data to preclinical-only molecules with striking rodent results. The ranking below is ordered by how much actual human data supports each compound's longevity-relevant effects.
Read articlePT-141 for Men: Off-Label Use Reality Check
PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women. Off-label use in men for libido and erectile concerns has grown substantially. The male-context evidence is thinner than the marketing suggests, and this sets it against PDE5 inhibitors.
Read articleIs Ozempic a Peptide? Yes — and So Are Wegovy & Mounjaro
One of the most common questions about GLP-1 medications has a clear answer: yes, they are peptides. This unpacks what that actually means, why the question causes so much confusion, and how FDA-approved peptide drugs differ from the 'research peptides' sold online.
Read articleBest Peptides for Weight Loss in 2026: An Evidence-Based Ranking
The weight-loss peptide landscape in 2026 ranges from FDA-approved blockbusters with deep clinical evidence to research-grade compounds with thin or absent human data. An honest ranking follows what the research actually supports.
Read articleWhat Is Cagrilintide? The Amylin Analog Explained
Cagrilintide is one of the most-watched peptides in obesity medicine, a long-acting amylin analog being developed by Novo Nordisk, most prominently as half of the CagriSema combination. What it is, how it works, and where it sits in the 2026 pipeline are all clearer than the CagriSema headlines suggest.
Read articleBest GLP-1 Medication in 2026: How to Choose
There is no single 'best' GLP-1 medication — the right choice depends on your goal, your health profile, your insurance, and your tolerance for injections. This lays out a practical decision framework for the approved options, plus what's coming next.
Read articleHow Long Do Reconstituted Peptides Last? A Storage & Shelf-Life Guide
The question people Google every month and never get a consistent answer to. Here is a class-by-class reference for reconstituted peptide stability, fridge, room temperature, and freezer, plus the chemistry of why peptides degrade and the one variable that matters more than temperature.
Read articlePeptide Half-Life Explained: Plasma Half-Life vs. Shelf Life
Every peptide page lists a half-life, and it is one of the most misread numbers in the whole field. Here is what plasma half-life actually measures, why it is completely separate from how long a vial lasts, and how conflating the two produces the contradictory answers you find online.
Read articleHow to Read a Peptide Certificate of Analysis (COA)
A COA is the one document that tells you what is actually in the vial, and most people either never see one or do not know what they are looking at. Here is a field-by-field walkthrough of HPLC purity, mass-spec identity, net peptide content, and the red flags that separate a real COA from a meaningless one.
Read articleLyophilized Peptides: What 'Freeze-Dried' Actually Means
Almost every research peptide ships as a lyophilized powder, and the first reaction is often that the vial looks empty. Here is what lyophilization is, why peptides are stored this way, why 5 mg can look like nothing, and how to handle the powder before it ever touches solvent.
Read articlePeptide Stacks Explained: How and Why Peptides Are Combined
Stacking, combining two or more peptides, is one of the most-discussed practices in the research-peptide community and one of the least-rigorously-studied. Here is what stacking actually means, the biological rationale behind common combinations, and the honest evidence gap that most stack discussions skip past.
Read articleBacteriostatic Water for Peptide Reconstitution Explained
Bacteriostatic water is the single most important variable in how long a reconstituted peptide stays safe to use, and most people who use it have no idea why it works. Here is what the 0.9% benzyl alcohol actually does, how it differs from sterile water and saline, and the regulatory and practical considerations that shape its availability.
Read articleHow to Calculate Peptide Doses: Reconstitution Math, IU Conversions, and Syringe Marks
If a peptide is sold by milligrams and dosed in micrograms, how does the math actually work? Here is the conversion logic that turns a peptide vial label into a syringe mark, concentration, dose, and the IU-vs-mL relationship, without the cargo-cult formulas that circulate online.
Read articleThe GLP-1 Titration Schedule: Why Slow, and What to Expect at Each Dose Step
Every GLP-1 drug, semaglutide, tirzepatide, liraglutide, starts at a low dose and steps up over months. The schedule is not arbitrary or just for caution: titration is what makes the GI side effects tolerable, and skipping ahead is the single biggest predictor of dropping out. Here is what the official titration schedules look like and the biology behind why they work.
Read articleBest Healing & Recovery Peptides in 2026: An Evidence-Based Ranking
The healing peptide landscape ranges from rodent-protocol research compounds with passionate user communities to FDA-approved drugs for narrow clinical indications. Here is an honest ranking by what the evidence actually shows, and what it does not.
Read articleBest Cognitive Peptides in 2026: An Evidence-Based Ranking
The cognitive peptide landscape mixes well-studied Russian-tradition compounds, FDA-approved drugs for specific neurological conditions, and biohacker favorites with thin evidence. Here is an honest ranking by what the published research actually supports.
Read articleBest Growth Hormone Secretagogues in 2026: An Evidence-Based Ranking
The GH secretagogue landscape ranges from FDA-approved drugs for narrow clinical indications to research-grade peptides widely used for performance, recovery, and body composition. Here is an honest ranking by mechanism, evidence, and what each one is actually good for.
Read articleHow Retatrutide Works in Plain English: The Triple-Agonist Mechanism
Retatrutide is the first triple-agonist obesity drug, activating three different receptors instead of one or two. Here is what that actually means, why it produces deeper weight loss than tirzepatide, and the trade-offs the third receptor introduces.
Read articleHow Dulaglutide (Trulicity) Works in Plain English
Dulaglutide is the GLP-1 drug that solved the half-life problem with antibody chemistry instead of fatty acid engineering. Here is what that means, why it lasts a week despite being a peptide, and how Trulicity fits into the modern GLP-1 landscape.
Read articleGLP-1 Medications and Surgery: Pre-Op Discontinuation Guidelines
GLP-1 medications slow gastric emptying, which is part of how they work but can create real aspiration risk under anesthesia. Here is what the ASA and surgical society guidelines actually recommend about discontinuing before surgery, why the guidance keeps evolving, and the practical pre-op checklist for patients.
Read articlePeptide Cycling: When and Why People Take Breaks (and When It Matters)
Cycling, taking deliberate breaks from a peptide, is common in biohacker communities but often poorly explained. Here is when receptor desensitization actually justifies cycling, when it does not, and what the evidence supports across the major peptide categories.
Read articleSubcutaneous vs Intramuscular Peptide Injection: When Each Is Used
Most peptides are injected subcutaneously, into the fatty layer under the skin, for slow, sustained absorption. A few are injected intramuscularly. Here is the difference between the two routes, why the choice matters pharmacologically, and which peptides commonly use which approach.
Read articleHow HGH Replacement Actually Works in Plain English
HGH replacement is the simplest concept in growth-hormone optimization, just inject the hormone, and the most strictly regulated. Here is what HGH actually does in the body, what 1-2 IU dosing means physiologically, and why GHRP and tesamorelin alternatives exist at all.
Read articleNAD+, NMN, NR, and IV NAD: What the Research Actually Shows
NAD vs NAD+, NMN vs NR vs buffered NAD+ vs IV, the names blur together and the marketing claims outrun the evidence. A practical walk through what each form actually is, what controlled trials show, and which form the data most supports.
Read articleRapamycin for Longevity: What the Evidence Actually Shows
Rapamycin is the most reproducible lifespan-extending drug in animal models, which is why the longevity community watches it closely. A plain-English read on the mTOR mechanism, the mouse data, the PEARL human trial, and the risks that keep it experimental.
Read articleUrolithin A: The Mitophagy Compound With Real Human Trials
Urolithin A is unusual among longevity supplements because it comes with randomized, placebo-controlled human trials. A look at the gut-microbiome origin, the mitophagy mechanism, the muscle and mitochondrial data, and the limits of the evidence.
Read articleSpermidine: Autophagy, Longevity, and the SmartAge Trial
Spermidine has a clear autophagy mechanism, strong animal data, and population studies linking it to lower mortality, alongside a cautionary chapter: its most rigorous human cognition trial came back negative. Both halves of that story matter.
Read articleTaurine and Aging: What the Science Actually Says
In 2023 a single paper turned a cheap energy-drink ingredient into a longevity headline. Two years on, the animal data still intrigues while the human premise has taken a serious hit, making taurine a case study in reading hype against evidence.
Read articleState of the Peptide Market 2026: Enforcement, Fallout, and What Comes Next
March 2026 reshaped the research-peptide market. Peptide Sciences shut down under DOJ enforcement; Amino Asylum was raided; Paradigm Peptides faced federal charges. The community that built protocols around these vendors is now reorganizing around a substantially changed access landscape. This article maps what happened, the regulatory context that drove it, and the structural changes facing anyone who relied on these supply chains.
Read articleWhat Are Exosomes, and Why Most of What's Sold Isn't What You Think
Exosomes are one of the most researched topics in regenerative medicine, and one of the most misrepresented in the commercial market. This maps what the science actually covers, why the plant-derived vs MSC-derived distinction matters, and what the FDA's current 2026 stance means for buyers in research-peptide and regenerative-medicine contexts.
Read articleBest Peptides for Hair Loss in 2026: An Evidence-Based Ranking
Hair loss has become one of the most-searched peptide topics in 2026, driven substantially by the GLP-1 weight-loss boom and its associated hair shedding. The peptide category has real players and real evidence gaps. Our ranking runs from the copper peptides with decades of cosmetic-grade data to the emerging community-adopted approaches.
Read articleBest Peptides for Joint Pain in 2026: What Actually Has Evidence
Joint pain drives substantial peptide interest. The community-adopted options range from research peptides with substantial rodent-model evidence to newer emerging compounds with better trial infrastructure. We sort them by evidence quality, with clear framing about what has clinical support and what remains preclinical-only.
Read articleBest Peptides for Skin Anti-Aging in 2026: Evidence-Based Rankings
The skin peptide category has the strongest evidence base in the entire peptide space. Cosmetic-grade peptides have decades of clinical trial evidence; the newer research peptide additions extend but don't replace that foundation. This ranks them evidence-first, from established cosmetic peptides through emerging systemic approaches.
Read articleBest Peptides for Sleep in 2026: Evidence-Based Options and Community Experience
Sleep has become one of the fastest-growing peptide categories in 2026, driven substantially by Andrew Huberman's public disclosure of Pinealon use for REM sleep and broader biohacker interest in circadian and mitochondrial optimization. The category has legitimate options with real preclinical evidence and community adoption. This maps what the peptide sleep landscape actually looks like.
Read articleHow to Read a Peptide Certificate of Analysis (COA): A Practical Guide
The Certificate of Analysis is the single most important document accompanying any peptide purchase. But most COAs are difficult to interpret without context, and vendors sometimes use COA formatting to obscure quality issues rather than reveal them. This guide walks through how to actually read a peptide COA, what to look for, what to question, and how to spot the red flags that indicate an unreliable product.
Read articlePeptide Storage Guide: How to Store Peptides for Maximum Stability
Storage is where most peptide degradation happens. A properly-manufactured 98%-pure peptide can degrade to unusable material in weeks if stored incorrectly. Conversely, appropriately-stored peptides can maintain stability for years. This is the practical framework for storing peptides before reconstitution, after reconstitution, and during travel.
Read articleCompounded vs FDA-approved GLP-1s
What's actually different between FDA-approved Wegovy / Zepbound and the compounded semaglutide and tirzepatide that proliferated during the shortage.
Read articleMuscle preservation on GLP-1s
DEXA-substudy data from the STEP and SURMOUNT trials on lean-mass loss during GLP-1 therapy, and what the research on resistance training and protein intake mitigation actually shows.
Read articleProtein intake while losing weight on a GLP-1
What the caloric-deficit literature says about protein targets, sources, and timing, and how that translates to GLP-1 users.
Read articleLifting while on semaglutide or tirzepatide
What the research supports about combining resistance training with GLP-1 therapy, and the practical adjustments most evidence-informed clinicians recommend.
Read articleSide effects & safety · 10 articles
Honest coverage of side effects, what's normal vs. concerning, and how to navigate them.
Peptide and GLP-1 Side Effects: A Practical Guide
Most side effects here are predictable, manageable, and temporary. A few are not. How to sort the nuisances from the warning signs, and where "manage it" becomes "stop and call someone."
Read articleGLP-1 Side Effects Week by Week: What to Expect
A practical timeline of GLP-1 side effects across the typical 6-month dose-escalation pattern. What's normal, what's worth a clinical conversation, and what management strategies actually help.
Read articleManaging GLP-1 Nausea: Practical Strategies That Actually Work
Nausea is the most common GLP-1 side effect and the most common reason patients discontinue therapy. This is an evidence-based playbook for managing it: what to eat, what to avoid, when to slow titration, and when to ask about antiemetic medications.
Read articleGLP-1 Medications and Mental Health: What the Evidence Shows
Reports of mood changes, depression, and suicidal ideation on GLP-1 medications have generated substantial concern and FDA review. This weighs what the data actually shows, where the signal is real, and what to watch for in your own experience.
Read articleGLP-1 Discontinuation: What Happens When You Stop
Many patients want or need to stop GLP-1 therapy at some point, for cost, side effects, surgery, pregnancy, or just wanting to be off medication. Discontinuation follows a fairly predictable arc: what happens during and after, the weight regain pattern, and strategies for minimizing rebound.
Read articleAre Peptides Safe? A Calibrated Guide to Risk by Category
The honest answer is 'it depends entirely on which peptide and how you're using it.' Some peptides have decades of safety data and FDA approval; others have essentially no human safety characterization. This guide segments the peptide landscape into risk tiers so you can calibrate your own decisions, not by vibes, but by what the evidence actually shows for each category.
Read article8 Peptides That Need Extra Caution (And Why)
Most peptides at responsible doses from reliable sources have favorable short-term safety profiles. A small subset have specific concerns that warrant extra scrutiny, theoretical or demonstrated cancer-promotion signals, cardiovascular effects, allergic reactions, water retention, or near-complete absence of human safety data. This article covers the eight that the practical framework treats differently from the general peptide pool, with the actual evidence behind each concern.
Read articlePeptide Drug Interactions: A Practical Guide
Most peptide users access peptides outside standard prescribing channels, which means no pharmacist is screening for interactions and no electronic health record is flagging combinations. Some interactions are well-characterized and clinically meaningful; others are theoretical but worth knowing. This guide is structured by the medication or condition you may already have, so you can find the interaction that matters before it matters.
Read articleManaging GLP-1 GI side effects
Nausea, reflux, constipation: what the trial data shows about incidence, duration, and mitigation strategies that have supporting evidence.
Read articleMental health, cravings, and addiction signals on GLP-1s
What the trial and observational evidence shows about food noise, alcohol cravings, and the mood-related effects of GLP-1 therapy.
Read articleLifestyle & long-term · 7 articles
Long-term and lifestyle considerations alongside peptide and GLP-1 therapy.
Ozempic Face: What Causes It and How to Prevent It
The term started as social-media shorthand and has become a defining concern for GLP-1 patients. This covers the actual biology behind facial volume loss during rapid weight loss, who is most affected, and the evidence-based prevention strategies that work.
Read articleWhat to Eat While on Semaglutide: A Practical Nutrition Guide
GLP-1 medications change appetite, satiety, and food tolerance in ways that make nutrition strategy more important, not less. A practical framework for eating well during semaglutide therapy follows: protein-first, foods that work, foods that don't, hydration, and the long-term habits that determine outcomes.
Read articleExercising on GLP-1 Medications: Resistance Training, Cardio, and Recovery
Exercise is the single most important non-pharmacological intervention during GLP-1 therapy, for lean-mass preservation, cardiovascular health, and long-term sustainability. This explains how training changes on these medications, with a practical framework for doing it well.
Read articleGLP-1 Therapy and Alcohol: Why Tolerance Changes
Many GLP-1 patients notice substantially altered alcohol tolerance, sometimes drinking less, sometimes getting drunk faster, sometimes losing interest in drinking entirely. The biology behind those changes is well characterized, and it has direct implications for safe use.
Read articleGH Optimization for Longevity: GHRPs, Tesamorelin, and Low-Dose HGH
The honest deep dive on the longevity-specific question: do 1-2 IU low-dose HGH, off-label tesamorelin, or research-grade GHRPs actually compare for long-term health, and how do the 10-50x cost differences factor in over years and decades of use? Calibrated against the evidence, with the unanswered questions named.
Read articleLong-term use and maintenance on GLP-1s
What the discontinuation, durability, and chronic-use data shows about staying on GLP-1 therapy over the long term.
Read articleSleep, energy, and daily life on GLP-1s
How GLP-1 therapy affects sleep, energy levels, and daily functioning, the under-discussed lifestyle dimensions of long-term therapy.
Read articleFrontier & pipeline · 20 articles
Coverage of upcoming drugs, trial readouts, and emerging combinations as they develop.
VERVE-102: PCSK9 Base Editing and the One-Shot Cholesterol Question
Not a peptide, but adjacent: a gene-editing therapy that switches off PCSK9 in the liver to lower LDL cholesterol with a single infusion. What the early Heart-2 trial data shows, and why the metabolic and longevity crowd is watching.
Read articleCagriSema Phase 3: What to Expect and When
CagriSema (cagrilintide + semaglutide) is the most-watched obesity-pharmacology combination in Phase 3 trials. This covers what the program is testing, what the Phase 2 data suggests we'll see, when readouts are expected, and what approval would mean.
Read articleRetatrutide: Release Date, Expected Magnitude, and What to Watch
The most-anticipated obesity medication of the late 2020s. We take stock of the Phase 3 program, the expected timeline to approval, what Phase 2 results suggest about clinical magnitude, and what is worth watching.
Read articleBimagrumab + GLP-1: The Muscle-Preservation Combination in Phase 3
Eli Lilly's Phase 3 program testing bimagrumab combined with tirzepatide is one of the most-watched developments in obesity pharmacology. This covers what the combination targets, what Phase 2 evidence supports, and what approval would mean for body composition outcomes.
Read articleThe Next 5 Years in Obesity Medicine: What to Watch
Obesity pharmacology is moving faster than any therapeutic class in modern medicine. The sections below cover what is most likely to reach the market between 2026-2030, what is worth watching, and what these developments mean for current and future patients.
Read articleMariTide (Maridebart Cafraglutide / AMG 133): The Once-Monthly GLP-1 Obesity Drug Explained
Amgen's MariTide is the most-watched drug in obesity pharmacology in 2026, once-monthly dosing, a GIP-receptor mechanism opposite to tirzepatide's, and a Phase 2 result that suggested weight loss continued after stopping injections. Here is what the trials actually show, why the monthly cadence matters, and what to expect from the Phase 3 readout.
Read articleOrforglipron Phase 3 Outlook: The First Oral Small-Molecule GLP-1
Lilly's orforglipron is positioning to be the first oral non-peptide GLP-1 receptor agonist, no injection, no peptide synthesis, no food-timing rules. Here is what the Phase 3 ACHIEVE program is measuring, how oral non-peptide compares with oral semaglutide, and why this approval may matter more for supply than for magnitude.
Read articleAmycretin: Novo's GLP-1 + Amylin Dual Agonist
Most dual-agonist obesity drugs combine GLP-1 with another incretin, tirzepatide's GIP, retatrutide's glucagon. Amycretin is different: it pairs GLP-1 with amylin, the appetite hormone behind cagrilintide, in a single molecule rather than a combination of two drugs. Phase 1 weight loss was striking. Here is what that means and where Phase 2 is heading.
Read articleOnce-Monthly GLP-1: The Coming Shift From Weekly to Monthly Dosing
Every approved GLP-1 drug is dosed at least weekly. MariTide is changing that. Once-monthly dosing is not just a convenience upgrade, it changes adherence economics, injection-site fatigue, and the long pharmacology tail in ways that may matter more than incremental gains in weight-loss magnitude. Here is what monthly cadence actually changes.
Read articleSurvodutide: Boehringer's GLP-1 / Glucagon Dual Agonist for Obesity and MASH
Survodutide pairs GLP-1 receptor agonism with glucagon receptor agonism, the same novel glucagon-arm strategy retatrutide uses, but without the GIP arm. Here is what that mechanism actually does, the Phase 2 data, and why both Eli Lilly and Boehringer Ingelheim are betting on glucagon as the next obesity-pharmacology lever.
Read articlePemvidutide: Altimmune's MASH-Focused GLP-1 / Glucagon Dual
Pemvidutide is the small-biotech entry in the GLP-1 / glucagon dual-agonist race, positioned primarily for MASH (fatty liver disease) rather than as a pure obesity drug. Here is what the molecule does, the Phase 2 data, and how the MASH-first strategy distinguishes it from survodutide and retatrutide.
Read articleMazdutide: Innovent's GLP-1 / Glucagon Dual Agonist for the Asian Market
Mazdutide is the GLP-1 / glucagon dual agonist developed primarily for the Chinese market, licensed from Eli Lilly's research, now an Innovent Biologics drug. Here is what the molecule does, the Phase 3 Chinese trial data, and how the Asia-first development pathway fits into the global GLP-1 landscape.
Read articleSetmelanotide and the MC4R Pathway: Rare Genetic Obesity Syndromes
Setmelanotide is an FDA-approved obesity drug that works through a completely different mechanism than GLP-1s, activating the MC4R receptor directly to restore signaling in patients with rare genetic obesity syndromes. Here is what the MC4R pathway actually does, why most 'common' obesity doesn't respond, and what setmelanotide teaches about obesity biology.
Read article ArticleThe February 2027 FDA PCAC Peptide Review: What's Next After July
FDA's compounding committee has five more peptides to review before the end of February 2027: GHK-Cu, LL-37, Melanotan II, Dihexa acetate, and PEG-MGF. After July, when the panel recommended six of seven compounds over its own reviewers' objections, the odds look different than the evidence alone would suggest.
Read articleFDA PCAC July 23-24, 2026: What's at Stake for BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP
The FDA's Pharmacy Compounding Advisory Committee recommended six of seven peptides at its July 23-24, 2026 meeting, overriding its own staff reviewers and reshaping compounding-pharmacy access for some of the most-discussed compounds in modern peptide medicine. This covers what is actually on the agenda, what each compound's evidence package looks like, what the possible outcomes are, and what users currently relying on these peptides should be watching for.
Read articleThe Next-Generation GLP-1 Pipeline: Novo Nordisk, Lilly, Amgen, Boehringer, Viking, and the 2027-2028 Landscape
The GLP-1 pipeline of 2026-2028 will reshape the obesity and diabetes treatment landscape. Multi-agonist compounds (GLP-1/GIP/glucagon triples), oral small-molecule agonists that could dramatically change access, and new mechanisms targeting fat-specific weight loss are all approaching approval or Phase 3 completion. This maps the pipeline as of mid-2026: what is approaching approval, what mechanisms are being tested, and how the market is likely to evolve.
Read articleAndrew Huberman's Peptides Masterclass with Dr. Bakri (June 2026): Compound-by-Compound
Andrew Huberman's June 1, 2026 Peptides Masterclass with Dr. Abud Bakri became one of the most-discussed peptide episodes ever released, reaching millions of listeners and driving substantial search interest in every compound the two covered. This walks through the episode compound by compound, with cross-links to our peptide pages so you can dig into the underlying evidence for each.
Read articleGLP-1 pipeline: 2026 and beyond
A field guide to the next-generation GLP-1, incretin, and metabolic peptide programs likely to reshape the landscape over the next several years.
Read articleLatest GLP-1 research
A curated digest of the most recent trial readouts, mechanistic papers, and clinical updates across the GLP-1 / incretin field.
Read articleCardiovascular and renal outcomes on GLP-1s
What SELECT, SUSTAIN-6, FLOW, and the broader cardiovascular outcomes literature show about GLP-1 therapy beyond glycemic control.
Read article